Key result
Rivaroxaban was associated with greater compliance and fewer bleeding and stroke events compared to warfarin in northern Chinese patients with atrial fibrillation.
Why the study?
To evaluate the safety and efficacy of warfarin versus rivaroxaban across different CHA2DS2-VASc score subgroups in patients with atrial fibrillation in northern China.
Does rivaroxaban improve adherence and reduce bleeding and stroke events compared to warfarin in northern Chinese patients with atrial fibrillation?
Cohort (n=387)
No
Does rivaroxaban improve adherence and reduce bleeding and stroke events compared to warfarin in northern Chinese patients with atrial fibrillation?
Rivaroxaban is associated with better adherence and fewer bleeding and stroke events compared to warfarin in northern Chinese patients with atrial fibrillation.
Answers are grounded in this paper and cite their sources.
Rivaroxaban may improve compliance and reduce bleeding versus warfarin across CHA2DS2-VASc strata in Chinese AF patients; hypothesis-generating, prospective trials needed.
Purpose: This study was aimed at evaluating the safety and efficacy of warfarin versus rivaroxaban in patients with atrial fibrillation (AF) and different CHA2DS2-VASc score subgroups in northern China. Methods: A retrospective cohort study was conducted to evaluate 387 patients with AF who received treatment at our institution between September 2018 and August 2019. The patients were divided into two groups receiving either warfarin (n=194) or rivaroxaban (n=193). Follow-up data were collected, including adherence, bleeding and ischemic stroke events. Results: The group receiving rivaroxaban showed better adherence than the group receiving warfarin. In the warfarin-treated group, bleeding incidents declined with increasing scores. In the warfarin-treated group, patients with scores of 2–3 had greater adherence and fewer stroke occurrences. The events of bleeding and stroke did not significantly differ in patients in the rivaroxaban-treated group with different scores. Conclusions: Compared with patients in the warfarin group with different CHA2DS2-VASc scores, those in the rivaroxaban group had greater compliance, and fewer bleeding and stroke events. Regardless of economic considerations, rivaroxaban is preferable for anticoagulative AF treatment in northern Chinese patients.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2023) conducted a cohort in atrial fibrillation (n=387). Rivaroxaban vs. Warfarin was evaluated on Adherence, bleeding, and ischemic stroke events. Rivaroxaban was associated with greater compliance and fewer bleeding and stroke events compared to warfarin in northern Chinese patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: